Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.08.2015 | case report | Ausgabe 15-16/2015

Wiener klinische Wochenschrift 15-16/2015

Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia

Zeitschrift:
Wiener klinische Wochenschrift > Ausgabe 15-16/2015
Autoren:
Univ. Doz. Dr. med. univ Arno Amann, Dr. Normann Steiner, Eberhard Gunsilius

Summary

Background

Recurrent epistaxis in hereditary haemorrhagic telangiectasia (HHT) patients significantly decreases their quality of life. Treatment in therapy refractory patients is limited although various options have been tested so far.

Case report

Herein, one patient is described that was treated for HHT for over 20 years with only intermediate benefits. As epistaxis duration and frequency increased continuously, bevacizumab 5 mg/kg was administered every 2 weeks. During the time of treatment (six doses) and up to 3 month afterwards clinical symptoms, blood pressure, cardiac output, pulmonary arterial hypertension (PAH), bleeding duration and frequency were assessed as criteria for treatment benefit.

Results

Duration and frequency of epistaxis decreased immediately after the first application resulting in reduced need of blood transfusions. After completion of six cycles, a further decrease in frequency and duration of bleeding was noted. Cardiac output and PAH decreased or remained stable, respectively, during time and after treatment. No increase in blood pressure could be found but a significant increase in heart rate was experienced after completion of all six applications. Unfortunately, the patient died due to a cerebral abscess.

Conclusion

Bevacizumab led to an improvement of HHT related epistaxis, refractory to other treatments.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 15-16/2015

Wiener klinische Wochenschrift 15-16/2015 Zur Ausgabe